Redeye retains its positive view of Proact following a strong Q4 report fueled by System sales.
Last year was very good for Aspo despite the Russia exit, in our view.
North America focus in Q4 When BTS reported its Q3 the organic growth in its biggest segment, North ...
Momentum looks solid Proact delivered an impressive Q4 report, growing sales 40% organically y-o-y, ...
Sleep Cycle published its preliminary Q4 2022 numbers on January 16, in light of the back-then ongoi...
Stark organisk tillväxt och stabil marginal Med flera samvarierande faktorer var marknaden fortsatt ...
Stor projektportfölj med bred geografisk exponering, en hög ESG profil och attraktiv värdering Eolus...
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and s...
Redeye believes that Sdiptech’s Q4 report was slightly better than our expectations.
Redeye states that the Q4 report was largely in line with estimates.
Takeaways from the Q4 report We were surprised by the pace with which the order bookings and the sal...
Ascelia’s leading SPARKLE study has recruited 71 (out of 80) patients, as announced earlier, and the...
Remedy reported a Q4 with revenue of EUR 13.6 million exactly in line with our estimates and an EBIT...
Redeye provides a research update on the back of Xavi Solutions Q4 2022 report.
Redeye comments on QleanAir’s final Q4 report. We understand that Cabin Solutions in Japan mainly re...
Pihlajalinna reports Q4 results on Feb 17. Last year the company positioned itself for growth, while...
Seamless Distribution Systems (”SDS eller “bolaget) meddelade den 8 februari 2023 preliminära siffro...
Good figures posted in Q4 Innofactor reported Q4 results in line with our expectations.
Q4 EBIT of SEK 138m, 4% above ABGSC Catella reported an EBIT of SEK 138m (145m) in Q4’22, which was ...
This morning, Vow announced that it has been awarded an order for converting four heat treatment fur...
